布地奈德联合异丙托溴铵治疗慢性阻塞性肺疾病患者临床疗效观察

Clinical efficacy of budesonide combined with ipratropium bromide in the treatment of patients with chronic obstructive pulmonary disease

目的探讨布地奈德联合异丙托溴铵治疗慢性阻塞性肺疾病(COPD)患者的临床疗效。方法选取2017年10月至2019年8月天津市武清区第二人民医院收治的COPD患者100例,随机分为联合组和对照组,每组50例。对照组使用布地奈德治疗,联合组使用布地奈德联合异丙托溴铵治疗。比较2组临床疗效、呼吸困难评分、COPD评估测试(CAT)评分、6min步行距离等指标。结果联合组总有效率(98.00%vs 78.00%)高于对照组,差异有统计学意义(P<0.05)。联合组呼吸困难评分、CAT评分低于对照组,6min步行距离长于对照组,差异有统计学意义(P<0.05)。结论布地奈德联合异丙托溴铵治疗COPD患者临床疗效显著,可明显改善临床相关指标,值得临床进一步推广。

Objective To explore the clinical efficacy of budesonide combined with ipratropium bromide in the treatment of patients with chronic obstructive pulmonary disease(COPD).Methods Totally 100 COPD patents in Wuqing Second People’s Hospital were selected from October 2017 to August 2019.They were randomly divided into combined group and control group,with 50 cases in each group.The control group was treated with budesonide,while the combined group was treated with budesonide and ipratropium bromide.The clinical effects,dyspnea score,CAT scores and indicators such as 6 min walking distance were compared between two groups.Results The total effective rate(98.00%)in the combined group was higher than that(78.00%)of the control group.The difference was statistically significant(P<0.05).Compared with the control group,the combined group had lower scores of dyspnea and CAT,and longer 6 min walking distance.The differences were statistically significant(P<0.05).Conclusion The clinical efficacy of budesonide combined with ipratropium bromide in the treatment of COPD patients is significant,which can significantly improve the clinical indicators of patients,and is worthy of further clinical promotion.